| scholarly article | Q13442814 |
| P50 | author | Kristina Unnebrink | Q42572520 |
| Gerd-Rüdiger Burmester | Q47261275 | ||
| Carlomaurizio Montecucco | Q47265945 | ||
| Athanasios George Tzioufas | Q92673448 | ||
| Xavier Mariette | Q93104907 | ||
| P2093 | author name string | Michel Malaise | |
| Johannes W J Bijlsma | |||
| Hartmut Kupper | |||
| Sonja Kary | |||
| Kristina Unnebrink | |||
| Indalecio Monteagudo-Sáez | |||
| P2860 | cites work | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
| Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. | Q30351543 | ||
| Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials | Q33243658 | ||
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis | Q34498486 | ||
| Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial | Q34530459 | ||
| Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont | Q34547981 | ||
| Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati | Q34662758 | ||
| Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study | Q34923104 | ||
| Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis | Q35551880 | ||
| Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed | Q35554130 | ||
| Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists | Q35554823 | ||
| Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists | Q35554865 | ||
| Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas | Q35555527 | ||
| Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis | Q35637322 | ||
| Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison | Q35637985 | ||
| Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study | Q35638208 | ||
| The benefit/risk profile of TNF-blocking agents: findings of a consensus panel | Q36155477 | ||
| Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis | Q36217646 | ||
| A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. | Q40374563 | ||
| Predictors of infection in rheumatoid arthritis | Q40629895 | ||
| Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial | Q41917264 | ||
| Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. | Q41946251 | ||
| Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis | Q44003346 | ||
| The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses | Q44240544 | ||
| Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. | Q44896512 | ||
| Infections in patients with rheumatoid arthritis treated with biologic agents | Q44952372 | ||
| The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study | Q45187063 | ||
| Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists | Q46525959 | ||
| Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy | Q46919825 | ||
| American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
| Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate | Q47784405 | ||
| Death rates and causes of death in patients with rheumatoid arthritis: a population-based study | Q47926341 | ||
| Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. | Q50779374 | ||
| Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden | Q57350007 | ||
| Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatolo | Q57751349 | ||
| The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales | Q70606503 | ||
| Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria | Q80298150 | ||
| The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had | Q82132610 | ||
| Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis | Q82190685 | ||
| Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice | Q83230837 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| adalimumab | Q348260 | ||
| P304 | page(s) | 732-739 | |
| P577 | publication date | 2007-02-28 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial | |
| P478 | volume | 66 |
| Q43280906 | 2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations |
| Q48252129 | Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. |
| Q28282655 | Adalimumab for the treatment of rheumatoid arthritis |
| Q38192659 | Adalimumab in the treatment of rheumatoid arthritis |
| Q27691822 | Advances in the treatment of rheumatoid arthritis. |
| Q44518151 | Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis |
| Q38096206 | Biological therapies for rheumatoid arthritis: progress to date |
| Q82332974 | CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis |
| Q37728019 | Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis |
| Q37157407 | Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study |
| Q38236144 | Clinical parameters and biomarkers for anti-TNF treatment prognosis in rheumatoid arthritis patients |
| Q43191366 | Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha |
| Q35143956 | Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. |
| Q33486150 | DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists |
| Q57177877 | Decreased IgG4 ACPA levels in responders and increased CD1c classical dendritic cells in non-responders of patients with rheumatoid arthritis under therapy |
| Q36577308 | Do patients with active RA have differences in disease activity and perceptions if anti-TNF naïve versus anti-TNF experienced? Baseline results of the optimization of adalimumab trial |
| Q34081925 | Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). |
| Q26859134 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update |
| Q33566374 | Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions |
| Q90334891 | Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts |
| Q48282725 | Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial |
| Q33573112 | Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project |
| Q33956485 | Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study |
| Q42597675 | Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis |
| Q37210207 | Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study |
| Q38108468 | Endemic fungal infections in inflammatory bowel disease associated with anti-TNF antibody therapy |
| Q35620336 | Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors |
| Q90911152 | Fractionated irradiation of right thorax induces abscopal damage on testes leading to decline in fertility |
| Q37206996 | Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis |
| Q37786627 | Golimumab: a new anti-TNF-α agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis |
| Q60919444 | IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis |
| Q33984823 | Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study |
| Q37358271 | Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature |
| Q37156636 | Infectious complications associated with monoclonal antibodies and related small molecules |
| Q46153168 | Leflunomide in combination with TNF-blockers for Methotrexate intolerance |
| Q35110153 | Lipid peroxidation-mediated inflammation promotes cell apoptosis through activation of NF-κB pathway in rheumatoid arthritis synovial cells |
| Q37358124 | Long-term use of adalimumab in the treatment of rheumatic diseases. |
| Q42442252 | Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis |
| Q37832130 | Monoclonal antibody therapy-associated neurological disorders |
| Q36633367 | Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis. |
| Q88239772 | Origins of Discordant Responses among 3 Rheumatoid Arthritis Improvement Criteria |
| Q86934388 | Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study |
| Q47136253 | Predictor of the Simplified Disease Activity Index 50 (SDAI 50) at Month 3 of bDMARD Treatment in Patients with Long-Established Rheumatoid Arthritis |
| Q34413310 | Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized cont |
| Q37358239 | Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis |
| Q34114195 | Reduction in sickness absence in patients with rheumatoid arthritis receiving adalimumab: data from a German noninterventional study |
| Q40315731 | Rheumatoid arthritis complicated with immunodeficiency-associated lymphoproliferative disorders during treatment with adalimumab |
| Q37294842 | Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines |
| Q30244019 | Rheumatoid arthritis. |
| Q26991673 | Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies |
| Q34065405 | Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry |
| Q37691205 | Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study |
| Q37894193 | TNF alpha antagonist therapy and safety monitoring |
| Q35617753 | The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses |
| Q37728840 | The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease |
| Q37804483 | The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review |
| Q38129037 | The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. |
| Q38173669 | The safety of biologic therapies in RA-associated interstitial lung disease |
| Q92627208 | The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus |
| Q36679764 | Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice |
| Q50703895 | Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospe |
| Q54978346 | Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety. |
| Q36823592 | Treating psoriasis with adalimumab. |
| Q47132835 | Treatment with Biologicals in Rheumatoid Arthritis: An Overview. |
| Q37802766 | Tuberculosis and anti-TNF treatment: experience of a central London hospital |
| Q30799235 | Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data |
| Q34818636 | Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials |
| Q37207061 | Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study |
| Q82719630 | [Infectious complications of biologic therapy in patients with rheumatoid arthritis] |
| Q38207759 | anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. |
Search more.